Table 2. ESBL susceptibility in Oman, Europe & USA.

	Oman		Europe14		USA14
	E. coli	K. pneumoniae	E. coli	K. pneumoniae	E. coli	K. pneumoniae
Pip-Taz	64.4%	43.6%	72.5%	38.6%	80.0%	42.1%
Cip	24.9%	39.6%	20.2%	57.5	20%	36.8

Pip-Taz: Piperacillin/Tazobactam; Cip: Ciprofloxacin. Europe & USA results adopted from Herman Goossensa et al.¹⁴